This is a Preprint and has not been peer reviewed. This is version 2 of this Preprint.
The long journey of a benzodiazepine
Downloads
Authors
Abstract
Medications make up 12-25% of health care’s greenhouse gas emissions production. By utilizing a life cycle analysis approach, this article lays out each step of production and disposal and estimates the global journey of a generic clonazepam pill. Generic clonazepam was selected because it is a commonly prescribed medication and is often linked to deprescribing initiatives due to its potential patient harms. A visual map was created to illustrate each step of the medications life cycle, from Active Pharmaceutical Ingredient (API) mining to patient usage. Our findings demonstrate that health care prescribing practices have tangible environmental impacts and manufacturers should continue to invest in operational streamlining to reduce their greenhouse gas emissions. Overall, there is a need for clinicians and leadership to become more aware of the connection between medication prescription and climate change so that healthcare systems can start to reduce its emission production.
DOI
https://doi.org/10.31223/X5XD5T
Subjects
Other Life Sciences
Keywords
Pharmaceutical manufacturing, prescribing practices, Greenhouse gas emissions, Life Cycle Assessment, Life Cycle Analysis, healthcare leadership, healthcare emissions
Dates
Published: 2024-03-08 06:32
Last Updated: 2024-05-27 12:44
Older Versions
License
CC BY Attribution 4.0 International
Additional Metadata
Conflict of interest statement:
there are no relevant competing interests of the authors
Data Availability:
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Metrics
Views: 1677
Downloads: 715
Comment #151 Bert Heirman @ 2024-03-11 08:37
Dear authors, mapping the supply chain of medicines is one thing, assessing their environmental footprint is another thing. Although supply chains might be global and complex, transportation impacts are usually not the footprint driver. Your conclusion that regionalization of supply reduces health care's GHG emissions is not substantiated in your work. You didn't compare the full life cycle of a current with an alternative approach. You didn't build life cycle inventories and didn't assess the impact. As such your work might be regarded as tendentious.
I encourage you to go further and effectively make a full LCA of the supply chain of the medicine in review and even of the healthcare pathway in which the medicine is being used. I refer to work by Debaveye et al: https://doi.org/10.1186/s12913-019-4247-2
All the best!